Trial Profile
A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 06 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Dec 2022.
- 26 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 May 2022.